Biotechnology News and Research

RSS

Spherix 2011 net loss decreases to $3.5 million

Spherix Incorporated – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today reported financial results for the year ended December 31, 2011, and recent and upcoming business highlights.

29 Mar 2012

First Edition: March 28, 2012

Today's headlines recap yesterday's Supreme Court action related to the constitutionality of the individual mandate and set the scene for day 3 of the oral arguments, which will tackle issues of severalbility and questions about the health law's Medicaid expansion.

28 Mar 2012

AABB issues new RBC transfusion guidelines

The transfusion of red blood cells is a common treatment in clinical practice. However, the level at which they are transfused varies based not only on a patient's health, but also is determined by what the administering physician deems appropriate. Today, the American Association of Blood Banks (AABB) has issued new guidelines, published in Annals of Internal Medicine, recommending that transfusion of red blood cells be considered at a hemoglobin threshold of 7 to 8 g/dL for stable adults and children.

28 Mar 2012

GE Healthcare, DiaGenic enter research collaboration to develop blood-based test for MCI

DiaGenic ASA today announced a research agreement to collaborate with GE Healthcare to develop a blood-based test using DiaGenic's peripheral gene expression profiling in patients with mild cognitive impairment, a disorder associated with risk for Alzheimer's Disease.

27 Mar 2012

Nanoscale sensor can conduct individual DNA sequencing

Researchers have devised a nanoscale sensor to electronically read the sequence of a single DNA molecule, a technique that is fast and inexpensive and could make DNA sequencing widely available.

27 Mar 2012

ImaginAb completes Series A financing

ImaginAb, Inc. a clinical-stage company developing in vivo imaging agents for Positron Emission Tomography (PET) based on antibody fragment technology, today announced the completion of a Series A financing – led by Novartis Venture Funds.

27 Mar 2012

ACS symposium focuses on biomimetics

Combining the secrets that enable water striders to walk on water and give wood its lightness and great strength has yielded an amazing new material so buoyant that, in everyday terms, a boat made from 1 pound of the substance could carry five kitchen refrigerators, about 1,000 pounds.

27 Mar 2012

FDA approves Teva's QNASL nasal aerosol corticosteroid

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved QNASL Nasal Aerosol, a new, "dry" nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.

26 Mar 2012

Study reveals mechanism by which AD may cause memory loss

Alzheimer's disease (AD) steals memory and ruins lives. Despite near-daily reports of promising new therapies, AD remains unchecked. Now a new study reveals the mechanism by which AD may cause memory loss, suggesting new therapies.

26 Mar 2012

Promising results from Esperion ETC-1002 Phase 2 clinical trial for dyslipidemia

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced positive results from a Phase 2 clinical trial for ETC-1002.

26 Mar 2012

Nordion introduces new custom dose feature in Canada, Europe for TheraSphere

Nordion Inc., a leading provider of products and services for the prevention, diagnosis and treatment of disease, today launched a new custom dose feature in Europe and Canada for TheraSphere, Nordion's Y-90 microsphere treatment for liver cancer.

26 Mar 2012

Positive results from Amgen's AMG 145 Phase 1b study on patients with LDL-C

Amgen announced today positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins. The study demonstrated that multiple doses of AMG 145 significantly reduced serum low density lipoprotein cholesterol (LDL-C), also known as "bad" cholesterol, by up to 81 percent versus placebo (maximum reduction) in subjects on low to moderate doses of statins/

26 Mar 2012

Islet Sciences acquires DTI

Islet Sciences, Inc., a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced the closing of the acquisition of DiaKine Therapeutics, Inc., a biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes which is now the Company's wholly owned subsidiary.

26 Mar 2012

FDA Advisory Committee to review Repligen's SecreFlo NDA on May 31

Repligen Corporation today announced that the U.S. Food and Drug Administration's Gastrointestinal Drugs Advisory Committee will meet on May 31, 2012 to discuss the Company's New Drug Application (NDA) for SecreFlo for the improved detection of pancreatic duct abnormalities in combination with magnetic resonance imaging (MRI) in patients with pancreatitis.

26 Mar 2012

New information service on Medicare and Medicaid EHR incentive programs

Proxy Capital today announced the launch of a new, free information service, MaxEHR.com. The MaxEHR.com website provides doctors and other medical professionals with the information they need to maximize their incentives and productivity from adopting and using electronic health records (EHR).

23 Mar 2012

Cardiff team receives European grants to develop 'RealTCut' surgical simulation

Highly realistic surgical simulation which reduces patient risk has become the 100th Cardiff University project to win an award under the European Union's prime research funding scheme, the Seventh Framework Programme.

23 Mar 2012

Study identifies ROS in the gaseous phase of cigarette smoke

A team of researchers led by A. K. Rajasekaran, PhD, Director of the Nemours Center for Childhood Cancer Research, has shown that a key protein involved in cell function and regulation is stopped by a substance present in cigarette smoke.

22 Mar 2012

Allen Institute for Brain Science receives $300M gift to expand scientific programs

The Allen Institute for Brain Science announced today that, given its achievements to date, Paul G. Allen has committed an additional $300 million to the Institute to significantly expand its scientific programs.

22 Mar 2012

GUCY2C gene mutation leads to familial diarrhea syndrome

When the intestines are not able to properly process our diet, a variety of disorders can develop, with chronic diarrhea as a common symptom. Chronic diarrhea can also be inherited, most commonly through conditions with genetic components such as irritable bowel syndrome. Researchers in Norway, India, and at the HudsonAlpha Institute for Biotechnology have identified one heritable DNA mutation that leads to chronic diarrhea and bowel inflammation.

22 Mar 2012

New genotype may be responsible for sharp rise in whooping cough

Australia's prolonged whooping cough epidemic has entered a disturbing new phase, with a study showing a new strain or genotype may be responsible for the sharp rise in the number of cases.

22 Mar 2012